[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antiviral-drugs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antiviral-drugs":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100558494","phase-2-adaptive-dengue-antiviral-platform-trial-100558494",false,"NCT06551844","Adaptive Dengue Antiviral Platform Trial","Adaptive Dengue Antiviral Platform Trial (ADAPT): a Phase 2 Randomized, Adaptive, Open Label Trial for Antiviral Screening in Patients With Early Symptomatic Dengue","ADAPT","Inclusion Criteria:\n\n* Female or male patients with a clinical diagnosis of dengue virus infection and less than 48 hours of fever\n* Positive NS1 rapid diagnostic test\n* \\>= 10 years or ≥ 18 years of age (depending on license of therapeutic being evaluated)\n* Patient is able to give written informed consent or assent for full participation in the study.\n* Agreement to stay in hospital for duration of the intervention (most will be 5 days) and follow-up visits at day 30 and 60 post enrolment.\n\nExclusion Criteria:\n\n* Meets criteria for severe dengue at baseline (severe plasma leakage leading to dengue shock syndrome, fluid accumulation with respiratory distress, severe bleeding, severe organ involvement - AST\u002FALT\\>1000 U\u002FL, impaired consciousness, multiple organ dysfunction)\n* Pregnancy (either clinically confirmed or by urine dipstick for human chorionic gonadotrophin hormone)\n* Breastfeeding women\n* Localising features suggesting an alternative\u002Fadditional diagnosis, e.g. pneumonia, sepsis\n* Renal failure (baseline eGFR \\\u003C 30ml\u002Fmin)\n* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders\n* History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed)\n* Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant\n* Participation or planned participation in a study involving the administration of an investigational compound within the past one month.","ALL","10 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection\n\n* Primary objectives:\n\n  * To determine the antiviral effectiveness of the experimental drug(s) in early dengue infection\n  * To assess the safety and tolerability of the experimental drug(s) in dengue patients\n* Secondary objective:\n\n  * To assess the effect of the experimental drug(s) in dengue patients on physiological, clinical and virological parameters",[27,28],"Dengue","Antiviral Drugs","RECRUITING","2026-04-24",{"date":32,"type":33},"2026-04-30","ACTUAL",{"date":35,"type":33},"2026-04-20",{"date":37,"type":21},"2030-12-31",{"name":39,"class":40},"Oxford University Clinical Research Unit, Vietnam","OTHER",2]